- In March 2022, Jazz Pharmaceuticals announced a definitive agreement to acquire Sunosi (solriamfetol), a medication used to treat excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The acquisition is expected to close in the second quarter of 2022. This strategic move aims to enhance Jazz's portfolio of treatments for sleep disorders
- In February 2022, Takeda Pharmaceutical Company Limited announced the submission of a New Drug Application (NDA) for TAK-998, also referred to as Wakixol, to the U.S. Food and Drug Administration (FDA). This innovative oral medication functions as a dopamine and norepinephrine reuptake inhibitor (DNRI) and is designed specifically to treat cataplexy in adult patients diagnosed with narcolepsy. The filing represents a significant step forward in Takeda's commitment to addressing the needs of those affected by narcolepsy
- In January 2022, Harmony Biosciences LLC announced the initiation of a Phase 3 clinical trial for pitolisant, a histamine H3 receptor antagonist. This trial aims to evaluate the efficacy of pitolisant in treating adults with narcolepsy experiencing excessive daytime sleepiness (EDS). The study represents a significant advancement in developing targeted therapies for individuals suffering from this debilitating symptom of narcolepsy
- In January 2020, Axsome Therapeutics, Inc., a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, secured an exclusive U.S. license from Pfizer Inc. This agreement grants Axsome access to Pfizer’s clinical and nonclinical data, as well as the intellectual property related to reboxetine, the active pharmaceutical ingredient in AXS-12, which is being developed for narcolepsy treatment. This collaboration is expected to enhance Axsome's capabilities in advancing AXS-12's development
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Type 1 Narcolepsy and Type 2 Narcolepsy), Drugs (Selective Histamine H3-Receptor Antagonist, Stimulants, Serotonin Reuptake Inhibitors, Tricyclic Antidepressants, Central Nervous System Depressant, and Others), Route of Administration (Oral and Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) – Industry Trends and Forecast to 2031
.
The Global Narcolepsy Treatment Market size was valued at USD 3.15 USD Billion in 2023.
The Global Narcolepsy Treatment Market is projected to grow at a CAGR of 10.5% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
